[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 269,242
  • Shares Outstanding, K 249,298
  • Annual Sales, $ 14,560 K
  • Annual Income, $ -63,530 K
  • EBIT $ -23 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.51
  • Price/Sales 19.01
  • Price/Cash Flow N/A
  • Price/Book 5.25

Options Overview Details

View History
  • Implied Volatility 301.43% (-12.06%)
  • Historical Volatility 49.96%
  • IV Percentile 93%
  • IV Rank 72.96%
  • IV High 383.76% on 03/27/26
  • IV Low 79.27% on 04/21/26
  • Expected Move (DTE 19) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 35
  • Volume Avg (30-Day) 82
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 5,919
  • Open Int (30-Day) 5,549
  • Expected Range 1.0800 to 1.0800

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.03
  • Number of Estimates 2
  • High Estimate $-0.02
  • Low Estimate $-0.03
  • Prior Year $-0.01
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0000 +8.00%
on 07/27/26
1.3800 -21.74%
on 07/06/26
-0.2300 (-17.56%)
since 06/30/26
3-Month
1.0000 +8.00%
on 07/27/26
1.5500 -30.32%
on 05/01/26
-0.4300 (-28.48%)
since 04/30/26
52-Week
0.9460 +14.16%
on 08/05/25
2.0900 -48.33%
on 11/03/25
+0.0500 (+4.85%)
since 07/30/25

Most Recent Stories

More News
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions,...

LCTX : 1.0800 (-2.70%)
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients...

LCTX : 1.0800 (-2.70%)
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today...

LCTX : 1.0800 (-2.70%)
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END

AVAI : 0.1210 (+5.31%)
BIOA : 9.04 (-63.62%)
LCTX : 1.0800 (-2.70%)
GERN : 1.2900 (-3.73%)
FATE : 2.45 (-2.39%)
Lineage Cell Therapeutics Q1 Earnings Call Highlights

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program in...

LCTX : 1.0800 (-2.70%)
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Launched New Corneal Endothelial...

LCTX : 1.0800 (-2.70%)
Lineage Cell Therapeutics Reports Tomorrow With OpRegen Trial Data Still Undefined

Barchart Research What to Expect from LCTX Earnings LCTX Generated May 11, 2026 Current Price $1.3100 EPS Estimate $$-0.02 Consensus Rating Strong Buy Average Move 2.07% Lineage Cell Therapeutics Reports...

LCTX : 1.0800 (-2.70%)
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today...

LCTX : 1.0800 (-2.70%)
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Gains in best corrected visual acuity (BCVA) of +9 letters at 36 months among patients with extensive coverage of OpRegen cell therapy to the geographic atrophy (GA) lesion site ...

LCTX : 1.0800 (-2.70%)
Lineage Announces Formation of Scientific Advisory Board

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions,...

LCTX : 1.0800 (-2.70%)

Business Summary

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are...

See More

Key Turning Points

3rd Resistance Point 1.1767
2nd Resistance Point 1.1533
1st Resistance Point 1.1167
Last Price 1.0800
1st Support Level 1.0567
2nd Support Level 1.0333
3rd Support Level 0.9967

See More

52-Week High 2.0900
Fibonacci 61.8% 1.6530
Fibonacci 50% 1.5180
Fibonacci 38.2% 1.3830
Last Price 1.0800
52-Week Low 0.9460

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.